Clinical trial
Oblimersen and Imatinib Mesylate in Treating Patients With Chronic Myelogenous…
NCT00049192 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00049192 |
|---|---|
| Title | Oblimersen and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia |
| Official title | A PHASE II STUDY OF G3139 (GENASENSE™, NSC # 683428 IND # 58842) + IMATINIB MESYLATE (GLEEVEC®, STI571) IN PATIENTS WITH IMATINIB-RESISTANT CHRONIC MYELOID LEUKEMIA |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Phase Chronic Myelogenous Leukemia, Relapsing Chronic Myelogenous Leukemia |
| Intervention type | Biological, Drug, Other |
| Interventions | oblimersen sodium, imatinib mesylate, laboratory biomarker analysis |
| Enrollment | 43 |
| Start date | Nov 1, 2002 |
| Primary completion | Nov 1, 2005 |
| First posted | Jan 27, 2003 |
| Last update posted | Jun 4, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: